GenVec Inc. to Release Fourth Quarter and Year-end 2012 Financial Results and Conduct a Conference Call on March 22, 2013

GAITHERSBURG, Md., March 15, 2013 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) will report financial results for the fourth quarter and year ended December 31, 2012 on Friday, March 22, 2013, before the U.S. financial markets open. The announcement will be followed by a webcast and conference call at 10:00 a.m. EDT to discuss the company's fourth quarter and 2012 financial results and 2013 business outlook.

To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 17801867. An audio replay of the conference call will be available starting at 1:00 p.m. EDT on March 22, 2013 through March 29, 2013. To listen to the audio replay, dial 855-859-2056 or 404-537-3406 and use Conference Replay ID: 17801867.

To access the webcast or the replay, go to www.genvec.com, click on "Investors and Media," and click on "Events and Presentations."

About GenVec
GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

SOURCE GenVec, Inc.